Combination of methylselenocysteine with tamoxifen inhibits MCF-7 breast cancer xenografts in nude mice through elevated apoptosis and reduced angiogenesis. 2009

Zengshan Li, and Latonya Carrier, and Aditi Belame, and Arunthavarani Thiyagarajah, and Virgilio A Salvo, and Matthew E Burow, and Brian G Rowan
Department of Structural & Cellular Biology, Tulane University School of Medicine, 1430 Tulane Ave, New Orleans, LA, 70112, USA.

To investigate the therapeutic effect of methylselenocysteine (MSC) combined with tamoxifen in MCF-7 breast cancer xenograft and the underlying mechanisms. MCF-7 breast cancer xenograft was established in ovariectomized female athymic nude mice and treated with tamoxifen and/or MSC. Tumor size was measured twice a week. Immunohistochemistry and TUNEL assays were used to measure ERalpha expression, ERalpha target genes (progesterone receptor (PR) and cyclin D1 expression), Ki-67 index, apoptosis and microvessel density. Combined treatment with tamoxifen and MSC synergistically inhibited tumor growth compared to MSC alone and tamoxifen alone. MSC alone or MSC + tamoxifen significantly reduced ERalpha, PR and cyclin D1, Ki67 index and microvessel density while increasing apoptosis in tumor tissues. These findings demonstrate synergistic growth inhibition of ERalpha positive breast cancer xenografts by combination of tamoxifen with organic selenium compounds. Organic selenium may provide added benefit when combined with tamoxifen in adjuvant therapy or prevention.

UI MeSH Term Description Entries
D008819 Mice, Nude Mutant mice homozygous for the recessive gene "nude" which fail to develop a thymus. They are useful in tumor studies and studies on immune responses. Athymic Mice,Mice, Athymic,Nude Mice,Mouse, Athymic,Mouse, Nude,Athymic Mouse,Nude Mouse
D009363 Neoplasm Proteins Proteins whose abnormal expression (gain or loss) are associated with the development, growth, or progression of NEOPLASMS. Some neoplasm proteins are tumor antigens (ANTIGENS, NEOPLASM), i.e. they induce an immune reaction to their tumor. Many neoplasm proteins have been characterized and are used as tumor markers (BIOMARKERS, TUMOR) when they are detectable in cells and body fluids as monitors for the presence or growth of tumors. Abnormal expression of ONCOGENE PROTEINS is involved in neoplastic transformation, whereas the loss of expression of TUMOR SUPPRESSOR PROTEINS is involved with the loss of growth control and progression of the neoplasm. Proteins, Neoplasm
D009376 Neoplasms, Hormone-Dependent Certain tumors that 1, arise in organs that are normally dependent on specific hormones and 2, are stimulated or caused to regress by manipulation of the endocrine environment. Hormone-Dependent Neoplasms,Hormone Dependent Neoplasms,Hormone-Dependent Neoplasm,Neoplasm, Hormone-Dependent,Neoplasms, Hormone Dependent
D009389 Neovascularization, Pathologic A pathologic process consisting of the proliferation of blood vessels in abnormal tissues or in abnormal positions. Angiogenesis, Pathologic,Angiogenesis, Pathological,Neovascularization, Pathological,Pathologic Angiogenesis,Pathologic Neovascularization,Pathological Angiogenesis,Pathological Neovascularization
D011897 Random Allocation A process involving chance used in therapeutic trials or other research endeavor for allocating experimental subjects, human or animal, between treatment and control groups, or among treatment groups. It may also apply to experiments on inanimate objects. Randomization,Allocation, Random
D011980 Receptors, Progesterone Specific proteins found in or on cells of progesterone target tissues that specifically combine with progesterone. The cytosol progesterone-receptor complex then associates with the nucleic acids to initiate protein synthesis. There are two kinds of progesterone receptors, A and B. Both are induced by estrogen and have short half-lives. Progesterone Receptors,Progestin Receptor,Progestin Receptors,Receptor, Progesterone,Receptors, Progestin,Progesterone Receptor,Receptor, Progestin
D001943 Breast Neoplasms Tumors or cancer of the human BREAST. Breast Cancer,Breast Tumors,Cancer of Breast,Breast Carcinoma,Cancer of the Breast,Human Mammary Carcinoma,Malignant Neoplasm of Breast,Malignant Tumor of Breast,Mammary Cancer,Mammary Carcinoma, Human,Mammary Neoplasm, Human,Mammary Neoplasms, Human,Neoplasms, Breast,Tumors, Breast,Breast Carcinomas,Breast Malignant Neoplasm,Breast Malignant Neoplasms,Breast Malignant Tumor,Breast Malignant Tumors,Breast Neoplasm,Breast Tumor,Cancer, Breast,Cancer, Mammary,Cancers, Mammary,Carcinoma, Breast,Carcinoma, Human Mammary,Carcinomas, Breast,Carcinomas, Human Mammary,Human Mammary Carcinomas,Human Mammary Neoplasm,Human Mammary Neoplasms,Mammary Cancers,Mammary Carcinomas, Human,Neoplasm, Breast,Neoplasm, Human Mammary,Neoplasms, Human Mammary,Tumor, Breast
D002455 Cell Division The fission of a CELL. It includes CYTOKINESIS, when the CYTOPLASM of a cell is divided, and CELL NUCLEUS DIVISION. M Phase,Cell Division Phase,Cell Divisions,Division Phase, Cell,Division, Cell,Divisions, Cell,M Phases,Phase, Cell Division,Phase, M,Phases, M
D003545 Cysteine A thiol-containing non-essential amino acid that is oxidized to form CYSTINE. Cysteine Hydrochloride,Half-Cystine,L-Cysteine,Zinc Cysteinate,Half Cystine,L Cysteine
D004357 Drug Synergism The action of a drug in promoting or enhancing the effectiveness of another drug. Drug Potentiation,Drug Augmentation,Augmentation, Drug,Augmentations, Drug,Drug Augmentations,Drug Potentiations,Drug Synergisms,Potentiation, Drug,Potentiations, Drug,Synergism, Drug,Synergisms, Drug

Related Publications

Zengshan Li, and Latonya Carrier, and Aditi Belame, and Arunthavarani Thiyagarajah, and Virgilio A Salvo, and Matthew E Burow, and Brian G Rowan
July 2000, Cancer letters,
Zengshan Li, and Latonya Carrier, and Aditi Belame, and Arunthavarani Thiyagarajah, and Virgilio A Salvo, and Matthew E Burow, and Brian G Rowan
July 2017, Molecular medicine reports,
Zengshan Li, and Latonya Carrier, and Aditi Belame, and Arunthavarani Thiyagarajah, and Virgilio A Salvo, and Matthew E Burow, and Brian G Rowan
January 2009, Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery,
Zengshan Li, and Latonya Carrier, and Aditi Belame, and Arunthavarani Thiyagarajah, and Virgilio A Salvo, and Matthew E Burow, and Brian G Rowan
May 1998, Breast cancer research and treatment,
Zengshan Li, and Latonya Carrier, and Aditi Belame, and Arunthavarani Thiyagarajah, and Virgilio A Salvo, and Matthew E Burow, and Brian G Rowan
November 1997, Cancer research,
Zengshan Li, and Latonya Carrier, and Aditi Belame, and Arunthavarani Thiyagarajah, and Virgilio A Salvo, and Matthew E Burow, and Brian G Rowan
January 1997, Oncology reports,
Zengshan Li, and Latonya Carrier, and Aditi Belame, and Arunthavarani Thiyagarajah, and Virgilio A Salvo, and Matthew E Burow, and Brian G Rowan
November 2008, Biochemical and biophysical research communications,
Zengshan Li, and Latonya Carrier, and Aditi Belame, and Arunthavarani Thiyagarajah, and Virgilio A Salvo, and Matthew E Burow, and Brian G Rowan
June 2003, Clinical cancer research : an official journal of the American Association for Cancer Research,
Zengshan Li, and Latonya Carrier, and Aditi Belame, and Arunthavarani Thiyagarajah, and Virgilio A Salvo, and Matthew E Burow, and Brian G Rowan
December 2004, Journal of toxicology and environmental health. Part A,
Zengshan Li, and Latonya Carrier, and Aditi Belame, and Arunthavarani Thiyagarajah, and Virgilio A Salvo, and Matthew E Burow, and Brian G Rowan
October 1998, Cancer letters,
Copied contents to your clipboard!